# KEYNOTE-585 (NCT03221426)

> Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: locally advanced gastric or gastroesophageal junction adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03221426
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Gastric Cancer; Gastroesophageal Junction Cancer
- Interventions: Pembrolizumab; Placebo; Cisplatin; Capecitabine; 5-fluorouracil; Docetaxel; Oxaliplatin; Leucovorin
- Enrollment: 1007
- Primary outcome: Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms
- Primary outcome: Pathological Complete Response (pathCR) Rate - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms
- Primary outcome: Overall Survival (OS) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms
- Primary outcome: Number of Participants Who Experienced One or More Adverse Events (AEs) - Pembrolizumab+FLOT and Placebo+FLOT Cohorts
- Primary outcome: Number of Participants Who Discontinued Study Treatment Due to an AE - Pembrolizumab+FLOT and Placebo+FLOT Cohorts

## Indexed commentary on KEYNOTE-585 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 51
- YouTube: 47
- Podcasts: 44
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-585-nct03221426

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03221426", "email": "<work email>"}; the inbox owner confirms by the emailed link.